Targets › ATP7B
5 programs from 5 companies in 5 trials: 4 Phase 1, 1 Phase 3; Metabolic and endocrine, Oncology; next expected readout Feb 2028.
Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. (UniProt, P35670)
Open in Phaseline: the race on ATP7B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Orphalan | TETA 4HCl Copper chelator | ATP7B | Phase 3 | Wilson's Disease | Feb 2028 |
| Prime Medicine | PM577a Prime editing therapy to correct p.H1069Q mutation in ATP7B gene | ATP7B | Phase 1 | Wilson Disease | Nov 2028 |
| Ultragenyx Pharmaceutical | UX701 (rivunatpagene miziparvovec) Nonreplicating recombinant gene transfer vector delivering functional ATP7B gene | ATP7B | Phase 1 | Wilson Disease | Mar 2029 |
| Vivet Therapeutics SAS | VTX-801 Replication-deficient recombinant adeno-associated viral vector (rAAV) with liver-tropic c | ATP7B | Phase 1 | Wilson's Disease | Jun 2029 |
| Dartmouth-Hitchcock Medical Center | Tetrathiomolybdate (TM) Copper-lowering agent that forms stable copper-molybdenum clusters, sequestering copper an | ATP7A, ATP7B | Phase 1 | Triple Negative Breast Cancer | Jun 2031 |
Wilson's Disease (2) Wilson Disease (2) Triple Negative Breast Cancer (1)
other (2), small molecule (2), mixed (1)
Vivet Therapeutics SAS (1) Ultragenyx Pharmaceutical (1) Dartmouth-Hitchcock Medical Center (1) Orphalan (1) Prime Medicine (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.